Identification and Visualization of Kinase-Specific Subpockets

The identification and design of selective compounds is important for the reduction of unwanted side effects as well as for the development of tool compounds for target validation studies. This is, in particular, true for therapeutically important protein families that possess conserved folds and have numerous members such as kinases. To support the design of selective kinase inhibitors, we developed a novel approach that allows identification of specificity determining subpockets between closely related kinases solely based on their three-dimensional structures. To account for the intrinsic flexibility of the proteins, multiple X-ray structures of the target protein of interest as well as of unwanted off-target(s) are taken into account. The binding pockets of these protein structures are calculated and fused to a combined target and off-target pocket, respectively. Subsequently, shape differences between these two combined pockets are identified via fusion rules. The approach provides a user-friendly visualization of target-specific areas in a binding pocket which should be explored when designing selective compounds. Furthermore, the approach can be easily combined with in silico alanine mutation studies to identify selectivity determining residues. The potential impact of the approach is demonstrated in four retrospective experiments on closely related kinases, i.e., p38α vs Erk2, PAK1 vs PAK4, ITK vs AurA, and BRAF vs VEGFR2. Overall, the presented approach does not require any profiling data for training purposes, provides an intuitive visualization of a large number of protein structures at once, and could also be applied to other target classes.

[1]  Friedrich Rippmann,et al.  TRAPP: A Tool for Analysis of Transient Binding Pockets in Proteins , 2013, J. Chem. Inf. Model..

[2]  Isidro Cortes-Ciriano,et al.  Proteochemometric modelling coupled to in silico target prediction: an integrated approach for the simultaneous prediction of polypharmacology and binding affinity/potency of small molecules , 2015, Journal of Cheminformatics.

[3]  Matthias Rarey,et al.  Exploiting structural information for drug-target assessment. , 2014, Future medicinal chemistry.

[4]  J. Kissil,et al.  Recent advances in the development of p21-activated kinase inhibitors , 2012, Cellular logistics.

[5]  Matthias Rarey,et al.  Analyzing the Topology of Active Sites: On the Prediction of Pockets and Subpockets , 2010, J. Chem. Inf. Model..

[6]  J. Chernoff,et al.  PAK signalling during the development and progression of cancer , 2013, Nature Reviews Cancer.

[7]  P. Prusis,et al.  Visually Interpretable Models of Kinase Selectivity Related Features Derived from Field-Based Proteochemometrics , 2013, J. Chem. Inf. Model..

[8]  Gerhard Klebe,et al.  Integrated Approach Using Protein and Ligand Information to Analyze Selectivity‐ and Affinity‐Determining Features of Carbonic Anhydrase Isozymes , 2006, ChemMedChem.

[9]  Adam R. Johnson,et al.  Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors. , 2014, Journal of medicinal chemistry.

[10]  K. Wilson,et al.  A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase , 1998, Protein science : a publication of the Protein Society.

[11]  K. Hoeflich,et al.  Inhibitors of p21-activated kinases (PAKs). , 2015, Journal of medicinal chemistry.

[12]  Jianwen A. Feng,et al.  Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors. , 2014, Journal of medicinal chemistry.

[13]  S. Licciulli,et al.  FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated Schwannomas* , 2013, The Journal of Biological Chemistry.

[14]  Joost C. M. Uitdehaag,et al.  A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets , 2012, British journal of pharmacology.

[15]  D. Bouzida,et al.  Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. , 2012, Journal of medicinal chemistry.

[16]  P. Bamborough System-based drug discovery within the human kinome , 2012, Expert opinion on drug discovery.

[17]  Stephen R. Johnson,et al.  3D Matched Pairs: Integrating Ligand- and Structure-Based Knowledge for Ligand Design and Receptor Annotation , 2013, J. Chem. Inf. Model..

[18]  Andreas Bender,et al.  Analyzing Multitarget Activity Landscapes Using Protein-Ligand Interaction Fingerprints: Interaction Cliffs , 2015, J. Chem. Inf. Model..

[19]  Lydia Siragusa,et al.  BioGPS Descriptors for Rational Engineering of Enzyme Promiscuity and Structure Based Bioinformatic Analysis , 2014, PloS one.

[20]  S. Knapp,et al.  The (un)targeted cancer kinome. , 2010, Nature chemical biology.

[21]  S. Tonegawa,et al.  Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486 , 2013, Proceedings of the National Academy of Sciences.

[22]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[23]  Nathanael Weill,et al.  Alignment-Free Ultra-High-Throughput Comparison of Druggable Protein-Ligand Binding Sites , 2010, J. Chem. Inf. Model..

[24]  Matthias Rarey,et al.  Fast Protein Binding Site Comparison via an Index-Based Screening Technology , 2013, J. Chem. Inf. Model..

[25]  G. Klebe,et al.  A new method to detect related function among proteins independent of sequence and fold homology. , 2002, Journal of molecular biology.

[26]  D. Fabbro,et al.  Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor. , 2015, ACS medicinal chemistry letters.

[27]  G. Cole,et al.  PAK in Alzheimer disease, Huntington disease and X-linked mental retardation , 2012, Cellular logistics.

[28]  E. Lionta,et al.  Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.

[29]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[30]  Yu-Wei Chang,et al.  An enriched structural kinase database to enable kinome‐wide structure‐based analyses and drug discovery , 2010, Protein science : a publication of the Protein Society.

[31]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.

[32]  L. Berg,et al.  Tec kinases in T cell and mast cell signaling. , 2007, Advances in immunology.

[33]  F. Javier Luque,et al.  MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories , 2011, Bioinform..

[34]  Friedrich Rippmann,et al.  Pocketome of Human Kinases: Prioritizing the ATP Binding Sites of (Yet) Untapped Protein Kinases for Drug Discovery , 2015, J. Chem. Inf. Model..

[35]  Paolo Benedetti,et al.  FLAP: GRID Molecular Interaction Fields in Virtual Screening. Validation using the DUD Data Set , 2010, J. Chem. Inf. Model..

[36]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[37]  R. Morphy Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[38]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[39]  H. Wolfson,et al.  Recognition of Functional Sites in Protein Structures☆ , 2004, Journal of Molecular Biology.

[40]  W. Peti,et al.  Molecular basis of MAP kinase regulation , 2013, Protein science : a publication of the Protein Society.

[41]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[42]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[43]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[44]  Anupama E. Gururaj,et al.  p21-activated kinases in cancer , 2006, Nature Reviews Cancer.

[45]  B. Tidor,et al.  Rational Approaches to Improving Selectivity in Drug Design , 2012, Journal of medicinal chemistry.

[46]  Daniel Kuhn,et al.  Combining Global and Local Measures for Structure-Based Druggability Predictions , 2012, J. Chem. Inf. Model..

[47]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[48]  J. Bajorath,et al.  Systematic Assessment of Molecular Selectivity at the Level of Targets, Bioactive Compounds, and Structural Analogues , 2016, ChemMedChem.

[49]  Daniel Moser,et al.  VAMMPIRE: a matched molecular pairs database for structure-based drug design and optimization. , 2013, Journal of medicinal chemistry.

[50]  G. Klebe,et al.  DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. , 2002, Journal of medicinal chemistry.

[51]  Gabriele Cruciani,et al.  BioGPS: Navigating biological space to predict polypharmacology, off‐targeting, and selectivity , 2015, Proteins.

[52]  E. A. O'neill,et al.  Molecular basis for p38 protein kinase inhibitor specificity. , 1998, Biochemistry.

[53]  M Hendlich,et al.  LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. , 1997, Journal of molecular graphics & modelling.

[54]  R. Guha,et al.  Profile of the GSK Published Protein Kinase Inhibitor Set Across ATP-Dependent and-Independent Luciferases: Implications for Reporter-Gene Assays , 2013, PloS one.

[55]  Chris de Graaf,et al.  KLIFS: a structural kinase-ligand interaction database , 2015, Nucleic Acids Res..

[56]  J. Field,et al.  PAK signaling in cancer , 2012, Cellular logistics.

[57]  S. Knapp,et al.  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.

[58]  H. Oki,et al.  Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. , 2012, Journal of medicinal chemistry.

[59]  P. LoRusso,et al.  Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology , 2008, Expert opinion on investigational drugs.

[60]  Eyke Hüllermeier,et al.  Functional Classification of Protein Kinase Binding Sites Using Cavbase , 2007, ChemMedChem.

[61]  A. Bender,et al.  Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.

[62]  R C Wade,et al.  Identifying targets for bioreductive agents: using GRID to predict selective binding regions of proteins. , 1989, Journal of molecular graphics.

[63]  I. Aliagas,et al.  Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors. , 2015, Journal of medicinal chemistry.

[64]  H. Matter,et al.  Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. , 2002, Journal of medicinal chemistry.

[65]  D. Knighton,et al.  Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth , 2010, Proceedings of the National Academy of Sciences.

[66]  G. Parmigiani,et al.  A multidimensional analysis of genes mutated in breast and colorectal cancers. , 2007, Genome research.

[67]  E. Goldsmith,et al.  Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.

[68]  P. Hajduk,et al.  Navigating the kinome. , 2011, Nature chemical biology.

[69]  Christoph Steinbeck,et al.  Classification and comparison of ligand-binding sites derived from grid-mapped knowledge-based potentials. , 2006, Journal of molecular graphics & modelling.

[70]  G. Kéri,et al.  Rational Drug Design of Kinase Inhibitors for Signal Transduction Therapy , 2011 .

[71]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[72]  Tomoyasu Ishikawa,et al.  Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. , 2013, Journal of medicinal chemistry.

[73]  Yan Yin,et al.  Discovery of potent and selective urea-based ROCK inhibitors: Exploring the inhibitor's potency and ROCK2/PKA selectivity by 3D-QSAR, molecular docking and molecular dynamics simulations. , 2015, Bioorganic & medicinal chemistry.

[74]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[75]  M. Baccarini,et al.  Raf kinases in cancer–roles and therapeutic opportunities , 2011, Oncogene.

[76]  G. Scapin Protein kinase inhibition: different approaches to selective inhibitor design. , 2006, Current drug targets.